Cargando…
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures
Idiopathic pulmonary fibrosis (IPF) is a form of chronic and irreversible fibrosing interstitial pneumonia of unknown etiology. Although antifibrotic treatments have shown a reduction of lung function decline and a slow disease progression, IPF is characterize by a very high mortality. Emerging evid...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861565/ https://www.ncbi.nlm.nih.gov/pubmed/36674438 http://dx.doi.org/10.3390/ijms24020925 |
_version_ | 1784874873108037632 |
---|---|
author | Vantaggiato, Lorenza Shaba, Enxhi Cameli, Paolo Bergantini, Laura d’Alessandro, Miriana Carleo, Alfonso Montuori, Giusy Bini, Luca Bargagli, Elena Landi, Claudia |
author_facet | Vantaggiato, Lorenza Shaba, Enxhi Cameli, Paolo Bergantini, Laura d’Alessandro, Miriana Carleo, Alfonso Montuori, Giusy Bini, Luca Bargagli, Elena Landi, Claudia |
author_sort | Vantaggiato, Lorenza |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is a form of chronic and irreversible fibrosing interstitial pneumonia of unknown etiology. Although antifibrotic treatments have shown a reduction of lung function decline and a slow disease progression, IPF is characterize by a very high mortality. Emerging evidence suggests that IPF increases the risk of lung carcinogenesis. Both diseases show similarities in terms of risk factors, such as history of smoking, concomitant emphysema, and viral infections, besides sharing similar pathogenic pathways. Lung cancer (LC) diagnosis is often difficult in IPF patients because of the diffuse lung injuries and abnormalities due to the underlying fibrosis. This is reflected in the lack of optimal therapeutic strategies for patients with both diseases. For this purpose, we performed a proteomic study on bronchoalveolar lavage fluid (BALF) samples from IPF, LC associated with IPF (LC-IPF) patients, and healthy controls (CTRL). Molecular pathways involved in inflammation, immune response, lipid metabolism, and cell adhesion were found for the dysregulated proteins in LC-IPF, such as TTHY, APOA1, S10A9, RET4, GDIR1, and PROF1. The correlation test revealed a relationship between inflammation- and lipid metabolism-related proteins. PROF1 and S10A9, related to inflammation, were up-regulated in LC-IPF BAL and serum, while APOA1 and APOE linked to lipid metabolism, were highly abundant in IPF BAL and low abundant in IPF serum. Given the properties of cytokine/adipokine of the nicotinamide phosphoribosyltransferase, we also evaluated its serum abundance, highlighting its down-regulation in LC-IPF. Our retrospective analyses of BAL samples extrapolated some potential biomarkers of LC-IPF useful to improve the management of these contemporary pathologies. Their differential abundance in serum samples permits the measurement of these potential biomarkers with a less invasive procedure. |
format | Online Article Text |
id | pubmed-9861565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98615652023-01-22 BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures Vantaggiato, Lorenza Shaba, Enxhi Cameli, Paolo Bergantini, Laura d’Alessandro, Miriana Carleo, Alfonso Montuori, Giusy Bini, Luca Bargagli, Elena Landi, Claudia Int J Mol Sci Article Idiopathic pulmonary fibrosis (IPF) is a form of chronic and irreversible fibrosing interstitial pneumonia of unknown etiology. Although antifibrotic treatments have shown a reduction of lung function decline and a slow disease progression, IPF is characterize by a very high mortality. Emerging evidence suggests that IPF increases the risk of lung carcinogenesis. Both diseases show similarities in terms of risk factors, such as history of smoking, concomitant emphysema, and viral infections, besides sharing similar pathogenic pathways. Lung cancer (LC) diagnosis is often difficult in IPF patients because of the diffuse lung injuries and abnormalities due to the underlying fibrosis. This is reflected in the lack of optimal therapeutic strategies for patients with both diseases. For this purpose, we performed a proteomic study on bronchoalveolar lavage fluid (BALF) samples from IPF, LC associated with IPF (LC-IPF) patients, and healthy controls (CTRL). Molecular pathways involved in inflammation, immune response, lipid metabolism, and cell adhesion were found for the dysregulated proteins in LC-IPF, such as TTHY, APOA1, S10A9, RET4, GDIR1, and PROF1. The correlation test revealed a relationship between inflammation- and lipid metabolism-related proteins. PROF1 and S10A9, related to inflammation, were up-regulated in LC-IPF BAL and serum, while APOA1 and APOE linked to lipid metabolism, were highly abundant in IPF BAL and low abundant in IPF serum. Given the properties of cytokine/adipokine of the nicotinamide phosphoribosyltransferase, we also evaluated its serum abundance, highlighting its down-regulation in LC-IPF. Our retrospective analyses of BAL samples extrapolated some potential biomarkers of LC-IPF useful to improve the management of these contemporary pathologies. Their differential abundance in serum samples permits the measurement of these potential biomarkers with a less invasive procedure. MDPI 2023-01-04 /pmc/articles/PMC9861565/ /pubmed/36674438 http://dx.doi.org/10.3390/ijms24020925 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vantaggiato, Lorenza Shaba, Enxhi Cameli, Paolo Bergantini, Laura d’Alessandro, Miriana Carleo, Alfonso Montuori, Giusy Bini, Luca Bargagli, Elena Landi, Claudia BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures |
title | BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures |
title_full | BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures |
title_fullStr | BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures |
title_full_unstemmed | BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures |
title_short | BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures |
title_sort | bal proteomic signature of lung adenocarcinoma in ipf patients and its transposition in serum samples for less invasive diagnostic procedures |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861565/ https://www.ncbi.nlm.nih.gov/pubmed/36674438 http://dx.doi.org/10.3390/ijms24020925 |
work_keys_str_mv | AT vantaggiatolorenza balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures AT shabaenxhi balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures AT camelipaolo balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures AT bergantinilaura balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures AT dalessandromiriana balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures AT carleoalfonso balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures AT montuorigiusy balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures AT biniluca balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures AT bargaglielena balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures AT landiclaudia balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures |